Rigel Pharmaceuticals has transformed its financial trajectory through commercializing three FDA-approved products—TAVALISSE, REZLIDHIA, and GAVRETO—that target hematologic and oncologic conditions with high unmet need. In 2025, Rigel reported a dramatic turnaround to operating and net profitability, driven primarily by rapid growth in TAVALISSE sales and leveraging cost controls. Future growth depends on advancing pipeline candidates like the IRAK1/4 inhibitor R289 and expanding indications for olutasidenib through strategic collaborations. However, competition from larger pharma, patent litigation, evolving healthcare regulations, pricing pressures, and reimbursement dynamics pose ongoing risks. Rigel’s capital allocation emphasizes reinvestment in development alongside stable liquidity without share buybacks or dividends currently.